{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:33:26Z","timestamp":1783017206587,"version":"3.54.6"},"reference-count":13,"publisher":"Royal Society of Chemistry (RSC)","issue":"30","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"am","delay-in-days":549,"URL":"http:\/\/rsc.li\/journals-terms-of-use"}],"content-domain":{"domain":["rsc.org"],"crossmark-restriction":true},"short-container-title":["Anal. Methods"],"abstract":"<jats:p>The mechanism of NTTP formation.<\/jats:p>","DOI":"10.1039\/d4ay00967c","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T20:21:18Z","timestamp":1719951678000},"page":"5288-5295","update-policy":"https:\/\/doi.org\/10.1039\/rsc_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploration and detection of nitrosamine impurity nitroso-STG-19 in sitagliptin tablets and API as well as nitrites in excipients by LC-MS\/MS methods"],"prefix":"10.1039","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-7666","authenticated-orcid":false,"given":"Yajie","family":"Hao","sequence":"first","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fu","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Wei","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Teng","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yin","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Cao","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Feng","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"},{"name":"School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimin","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Chiral Drugs, Lunan Pharmaceutical Group, Fei County, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"292","published-online":{"date-parts":[[2024]]},"reference":[{"key":"D4AY00967C\/cit1\/1","volume-title":"List of Classifications \u2013 IARC Monographs on the Identification of Carcinogenic Hazards to Humans","year":"2023","unstructured":"List of Classifications \u2013 IARC Monographs on the Identification of Carcinogenic Hazards to Humans ,  https:\/\/who.int ,  https:\/\/monographs.iarc.who.int\/list-of-classifications , accessed January  2023"},{"key":"D4AY00967C\/cit2\/1","volume-title":"FDA statement on FDA's ongoing investigation into valsartan impurities and recalls and an update on FDA's current findings|FDA","year":"2023","unstructured":"FDA statement on FDA's ongoing investigation into valsartan impurities and recalls and an update on FDA's current findings|FDA ,  https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-impurities-and-recalls-and-update-fdas-current , accessed January  2023"},{"key":"D4AY00967C\/cit3\/1","volume-title":"M7 Mutagenic Impurities, M7(R2), Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk","year":"2023","unstructured":"M7 Mutagenic Impurities, M7(R2), Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk ,  https:\/\/www.ich.org\/page\/multidisciplinary-guidelines , accessed April  2023"},{"issue":"3","key":"D4AY00967C\/cit4\/1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"Michael","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"D4AY00967C\/cit5\/1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3810\/pgm.2010.09.2215","volume":"122","author":"Nadeau","year":"2010","journal-title":"Postgrad. Med."},{"key":"D4AY00967C\/cit6\/1","volume-title":"FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity|FDA","year":"2022","unstructured":"FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity|FDA ,  https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-works-avoid-shortage-sitagliptin-following-detection-nitrosamine-impurity , accessed September  2022"},{"issue":"5","key":"D4AY00967C\/cit7\/1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","volume":"112","author":"Horne","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"D4AY00967C\/cit9\/1","first-page":"353","volume":"57","author":"Loeppky","year":"1984","journal-title":"IARC Sci. Publ."},{"issue":"3","key":"D4AY00967C\/cit10\/1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1039\/d2ay01821g","volume":"15","author":"Wang","year":"2023","journal-title":"Anal. Methods"},{"key":"D4AY00967C\/cit11\/1","doi-asserted-by":"publisher","first-page":"115861","DOI":"10.1016\/j.jpba.2023.115861","volume":"238","author":"Jire\u0161","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1\u20132","key":"D4AY00967C\/cit12\/1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0021-9673(03)00735-0","volume":"1002","author":"Stalikas","year":"2003","journal-title":"J. Chromatogr. A"},{"key":"D4AY00967C\/cit13\/1","volume-title":"International Conference on Harmonization (ICH), Q2 (R1): validation of analytical procedures: text and methodology","year":"2023","unstructured":"International Conference on Harmonization (ICH), Q2 (R1): validation of analytical procedures: text and methodology ,  https:\/\/www.ich.org\/LOB\/media\/MEDIA41\u201310\/2006 , accessed January  2023"},{"key":"D4AY00967C\/cit14\/1","doi-asserted-by":"publisher","DOI":"10.31003\/USPNF_M99525_02_01","volume-title":"United States Pharmacopeia. General Chapter, \u3008736\u3009 Mass Spectrometry. USP-NF","year":"2023","unstructured":"United States Pharmacopeia. General Chapter, \u3008736\u3009 Mass Spectrometry. USP-NF ,  Rockville, MD ,  2023 ,  10.31003\/USPNF_M99525_02_01"}],"container-title":["Analytical Methods"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.rsc.org\/en\/content\/articlepdf\/2024\/AY\/D4AY00967C","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:34:00Z","timestamp":1783013640000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.rsc.org\/ay\/article\/16\/30\/5288-5295\/837128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":13,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1039\/d4ay00967c","relation":{},"ISSN":["1759-9660","1759-9679"],"issn-type":[{"value":"1759-9660","type":"print"},{"value":"1759-9679","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}